Obesity Abstracts

Background: Approximately 15-25% of the world population has non-alcoholic fatty liver disease (NAFLD) and nearly quarter go on to develop non-alcoholic steatohepatitis (NASH). Obesity and T2DM are strong risk factors with prevalence of NAFLD rising to 90% in obesity and 60% in T2DM. Liver biopsy remains the gold standard in diagnosis and prognosis; nevertheless, it is expensive and invasive. The underlying fibrosis stage is key in determining clinical outcome...

Liraglutide 3 mg daily is an approved, prescription injectable GLP-1 receptor agonist, which can reduce weight in patients with obesity, with or without obesity complications. We conducted a 24-week, open-label real-world study involving 62 participants with a BMI >30 kg/m2 or >27 kg/m2 if they had co-existing dyslipidaemia or hypertension. No patients had type 2 diabetes. Patients received once-daily subcutaneous liraglutide 3.0 mg, alongside NHS...